Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Mark Kinarney - VP, IR Mary Heino - President and CEO Paul Blanchfield – COO Robert Marshall - CFO and Treasurer Conference Call Participants Roanna Ruiz - SVB Securities Larry Solow - CJS Securities Anthony Petrone - Mizuho Group Richard Newitter - Tuist Matt Taylor - Jefferies Justin Walsh - Jones Trading Yuan Zhi - B. Riley Operator Good morning, and welcome to the Lantheus Third Quarte ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2022 Earnings Conference Call August 4, 2022 8:08 AM ET Company Participants Mark Kinarney - Senior Director, Investor Relations Mary Heino - President and Chief Executive Officer Robert Marshall - Chief Financial Officer and Treasurer Paul Blanchfield - Chief Commercial Officer Conference Call Participants Richard Newitter - Truist Company Zach Weiner - Jefferies Roanna Ruiz - SVB Securities Larry Solow - CJS Securities Anthony Petrone - Mizuho Securities Operator ...

Second Quarter 2022 Results August 4, 2022 © 2022 Lantheus. All rights reserved. 1 Mary Anne Heino President and CEO Bob Marshall CFO and Treasurer 2Q 2022 Highlights & Business Update 2Q 2022 Operational Update 2Q 2022 Financial Update Closing Remarks Q&A © 2022 Lantheus. All rights reserved. Mark Kinarney Vice President, Investor Relations Paul Blanchfield Chief Operating Officer 2 Safe Harbor Statements 3 Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 | | - ...

1 T M Investor Presentation May 2022 w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d Safe Harbor Statements 2 Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act o ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2022 Results Earnings Conference Call April 29, 2022 8:00 AM ET Company Participants Mark Kinarney - Senior Director, Investor Relations Mary Anne Heino - President and Chief Executive Officer Paul Blanchfield - Chief Commercial Officer Robert Marshall Jr. - Chief Financial Officer and Treasurer Conference Call Participants Richard Newitter - Truist Securities Danielle Antalffy - SVB Leerink Zach Wiener - Jefferies Lawrence Solow - CJS Securities Operator Good mornin ...

FIND First Quarter 2022 Financial Results April 29, 2022 w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d 1 Mary Anne Heino President and CEO Bob Marshall CFO and Treasurer Paul Blanchfield Chief Commercial Officer Mark Kinarney Sr. Director, Investor Relations | --- | --- | --- | |-------|--------------------------------------|-------| | | 1Q 2022 Highlights & Business Update | | | | | | w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n ...

Product Launch and Market Potential - PYLARIFY, an F 18-labeled PET imaging agent, was commercially launched in the U.S. in June 2021 following FDA approval on May 27, 2021[106]. - The market potential for all PSMA PET imaging agents in the U.S. is estimated to be up to 250,000 annual scans, with specific breakdowns for different patient categories[108]. - PYLARIFY's commercial launch involved significant investment in hiring additional employees for sales, marketing, and quality assurance[112]. - The company has established a nationwide network of third-party manufacturing facilities (PMFs) to produce PYLARIFY, which requires separate FDA approval for each site[112]. - PYLARIFY received Healthcare Procedure Coding System (HCPCS) code effective January 1, 2022, and was granted Transitional Pass-Through Payment Status by CMS, which is set to expire on December 31, 2024[114]. - The company actively pursues patents for PYLARIFY, with four Orange Book-listed patents in the U.S. expiring in 2030 and 2037[115]. - PYLARIFY AI, an artificial intelligence software for analyzing PYLARIFY scans, was commercially launched in November 2021 after receiving FDA 510(k) clearance and CE marking[117]. - The company is expanding its geographic coverage and market access for PYLARIFY to better serve the U.S. prostate cancer community[111]. - A strategic collaboration with Novartis was announced in March 2022 to include PYLARIFY in prostate cancer trials with Pluvicto[109]. - The company emphasizes the importance of obtaining adequate coding, coverage, and payment for PYLARIFY to ensure its commercial viability[114]. Financial Performance - Revenues for the three months ended March 31, 2022, were $208.88 million, a 125.8% increase from $92.51 million in the same period of 2021[142]. - Gross profit for the same period was $129.07 million, representing a 214.6% increase compared to $41.03 million in 2021[142]. - Operating income increased to $58.93 million, up 277.2% from $15.62 million in the prior year[142]. - Net income for the three months ended March 31, 2022, was $42.96 million, a 376.9% increase from $9.01 million in 2021[142]. - PYLARIFY generated $92.78 million in revenue, contributing significantly to the overall revenue growth[145]. - Strategic partnerships and other revenue increased by 443.9% to $28.58 million, driven by a $24.0 million revenue recognition from the Novartis Agreement[145]. - Sales and marketing expenses rose to $20.35 million, a 43.6% increase from $14.17 million in the prior year, primarily due to commercialization activities for PYLARIFY[150]. - Research and development expenses increased by 17.8% to $12.20 million, reflecting ongoing investment in product development[154]. - The effective tax rate decreased to 25.8% in Q1 2022 from 37.2% in Q1 2021, primarily due to increased stock compensation benefits[158]. - Net cash provided by operating activities was $10.26 million for the three months ended March 31, 2022, compared to $9.82 million in the prior year[161]. Product Development and Strategic Initiatives - The company is committed to expanding its oncology portfolio, with ongoing clinical trials and collaborations, including a Phase 3 trial for LMI 1195[136]. - Strategic partnerships in the microbubble franchise are being developed, including collaborations with Allegheny Health Network and other companies for various medical applications[139]. - The company continues to evaluate opportunities for acquisitions and collaborations to enhance its product portfolio and drive future growth[135]. - DEFINITY sales are anticipated to continue growing, with over 80% market share in the U.S. echocardiography ultrasound enhancing agents as of December 31, 2021[119]. - The company holds five Orange Book-listed method of use patents for DEFINITY, expiring between 2035 and 2037, and is actively pursuing additional patents internationally[120]. - DEFINITY RT, a modified formulation of DEFINITY, became commercially available in Q4 2021, allowing for room temperature storage and shipment[121]. - A strategic arrangement with SHINE Medical Technologies for Mo-99 supply is expected to commence in 2023, providing three years of supply[125]. - A Manufacturing and Supply Agreement with JHS for DEFINITY and other products runs through December 31, 2027, ensuring specified annual purchase quantities[126]. - The company completed a specialized in-house manufacturing facility for DEFINITY, receiving FDA approval for commercial manufacturing in February 2022[127]. Challenges and Risks - The COVID-19 pandemic has impacted sales and operations, particularly affecting DEFINITY sales due to hospital staffing challenges and procedure declines[130][131]. - The company is vulnerable to supply chain shortages and disruptions, which could impact financial performance and may necessitate expense reductions[179]. - The company is required to make mandatory prepayments of the 2019 Term Loans under certain circumstances, with an amortization rate of 5.0% per year through September 30, 2022, increasing to 7.5% thereafter[168]. - The company has a total net leverage ratio limit of 3.50 to 1.00 and an interest coverage ratio limit of 3.00 to 1.00 as per the financial covenants in the 2019 Credit Agreement[171]. - The company may need to finance future capital requirements through public or private equity offerings, debt financings, or other strategic alternatives if cash resources become insufficient[180]. - The company assumed Progenics' outstanding debt of $40.2 million as a result of the Progenics Acquisition[173]. - The company voluntarily repaid the entire outstanding principal of the Royalty-Backed Loan amounting to $30.9 million on March 31, 2021[174]. - The company has a 2019 Revolving Facility with a maximum principal amount of $200.0 million, including sub-facilities for letters of credit ($20.0 million) and swingline loans ($10.0 million) for working capital and general corporate purposes[169].

1 ntheus Barclays Global Healthcare Conference Presentation March 15, 2022 FIND w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d Safe Harbor Statements 2 Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provis ...

1 T M Investor Presentation February 2022 w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d Safe Harbor Statements 2 Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities ...